22902-82-5

Basic information

• Product Name: 4-Chloro-3-(trifluoromethyl)phenylacetonitrile
• Synonyms: 2-[4-chloro-3-(trifluoroMethyl)phenyl]acetonitrile;4-Chloro-3-(trifluoromethyl)benzyl cyanide;4-Chloro-3-trifluoromethylbenzeneacetonitrile;Benzeneacetonitrile, 4-chloro-3-(trifluoromethyl)-
• CAS NO: 22902-82-5
• Molecular Formula: C₉H₅ClF₃N
• Molecular Weight: 219.6
• Mol File: 22902-82-5.mol

Chemical Properties

• Boiling Point: 256℃
• Flash Point: 109℃
• Appearance: /
• Density: 1.363
• Vapor Pressure: 0.0518mmHg at 25°C
• Refractive Index: 1.477
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 4-Chloro-3-(trifluoromethyl)phenylacetonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chloro-3-(trifluoromethyl)phenylacetonitrile(22902-82-5)
• EPA Substance Registry System: 4-Chloro-3-(trifluoromethyl)phenylacetonitrile(22902-82-5)

Safety Data

• Hazardous Substances Data: 22902-82-5(Hazardous Substances Data)

Usage

Chemical Properties

Off-white crystalline

InChI:InChI=1/C9H5ClF3N/c10-7-2-1-6(3-4-14)8(5-7)9(11,12)13/h1-2,5H,3H2

Upstream product

• 261763-23-9 4-(bromomethyl)-1-chloro-2-(trifluoromethyl)benzene 
• 143-33-9 sodium cyanide 
• 773837-37-9 sodium cyanide 
• 65735-71-9 (4-chloro-3-(trifluoromethyl)phenyl)methanol 
• 151-50-8 potassium cyanide 

Downstream Products

• 950995-12-7 2-[4-chloro-3-(trifluoromethyl)phenyl]propanoic acid 
• 1432048-95-7 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-hydroxy cyclobutanecarbonitrile 
• 1432048-98-0 (1-(4-chloro-3-(trifluoromethyl)phenyl)-3,3-difluorocyclobutyl)(pyridin-2-yl)methanone 
• 1432048-97-9 1-(4-chloro-3-(trifluoromethyl)phenyl)-3,3-difluorocyclobutanecarbonitrile 
• 1432048-96-8 1-(4-chloro-3-(trifluoromethyl)phenyl)-3-oxocyclobutanecarbonitrile 
• 1432048-94-6 {1-[4-chloro-3-(trifluoromethyl)phenyl]-3,3-difluorocyclobutyl}(pyridin-2-yl)methanol 
• 1268445-20-0 1-[4-chloro-3-(trifluoromethyl)phenyl]cyclopropanecarbonitrile 
• 1268444-90-1 1-[4-chloro-3-(trifluoromethyl)phenyl]cyclopropanecarboxylic acid 
• 1268445-17-5 (4R)-4-{[2-chloro-4-(2,2,2-trifluoroethoxy)phenyl]sulfonyl}-1-({1-[4-chloro-3-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)-N-(1-cyanocyclopropyl)-L-prolinamide 
• 1268444-89-8 (4R)-4-[(2-chlorophenyl)sulfonyl]-1-({1-[4-chloro-3-(trifluoromethyl)phenyl]cyclopropyl}carbonyl)-N-(1-cyanocyclopropyl)-L-prolinamide 
• 219909-53-2 (+/-)-2,6-dichloro-α-[4-chloro-3-(trifluoromethyl)phenyl]-4-nitrobenzene-acetonitrile 
• 22902-86-9 2-[4-chloro-3-(trifluoromethyl)phenyl]acetic acid 
• 875401-98-2 2-(4-chloro-3-trifluoromethyl-phenyl)-ethylamine 

Relevant articles and documents

ANTAGONISTS OF CHEMOKINE RECEPTORS

Compounds are provided that act as potent antagonists of the CCR1 receptor, and have in vivo anti-inflammatory activity. The compounds are generally aryl piperazine derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR1-mediated diseases, and as controls in assays for the identification of competitive CCR1 antagonists.

BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS

A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R1: -COR9 (wherein R9: alkyl, optionally substituted alkoxy or optionally substituted amino); R2: H, OH, alkoxy, optionally substituted amino, etc.; R3: H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R4 and R5: H, optionally substituted alkyl, halogeno, etc.; R6 and R7: H, alkyl; R8: -X2R10 [wherein R10: -COR11 (wherein R11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), -SO2R12 (wherein R12: optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X2: single bond, optionally substituted alkylene, etc.]; X1: -NH-, -O-, -S-, etc.; Y1: optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y2: optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

Heteroaryl and benzyl amide compounds

Compounds of formula I wherein R1, R2, R4, R5, A, B, D and n are as defined, and pharmaceutically acceptable salts thereof, processes for their preparation, their use as pharmaceuticals and pharmaceutical compositions comprising them.

Heterobicyclic amide compounds

Compounds of formula I processes for their preparation and pharmaceutical compositions comprising them.

TISSUE FACTOR PRODUCTION INHIBITOR

A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

Indole, indazole and indoline derivatives as CETP inhibitors

The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are mediated by CETP inhibitors.